I would like to personally invite you to attend the 2017 ISPE/FDA/PQRI Quality Manufacturing Conference, jointly sponsored by and organized with the FDA. If you have been to one of the previous Quality Manufacturing Conferences, you have an idea of the value of this opportunity. If you have never been to this conference before you will immediately see how important and relevant this is to your area of expertise in the manufacturing life cycle. This year promises to meet and exceed your expectations by emphasizing the top priorities from CDERs Office of Pharmaceutical Quality (OPQ) and Office of Compliance and the Office of Global Regulatory Policy and Operations. Highlights of the conference include:
And that is just the tip of the iceberg! Additional highlights include:
Calling all Young Professionals, Senior Leaders, Development, Quality, Engineering, Facility, and Manufacturing Professionals, and everyone involved in the life cycle of manufacturing medicines for patient needs today and in the future, you need to attend! I hope to see you there!
P.S. Don’t miss the Data Integrity Workshop on June 4th, immediately before the 2017 ISPE/FDA/PQLI Quality Manufacturing Conference, with FDA Compliance, Pharmaceutical Industry Compliance and ISPE GAMP® experts, facilitating an interactive workshop on successfully implementing a robust data integrity program avoiding compliance issues. Sign up now: www.ISPE.org/2017-Data-Integrity-Workshop/Register
In the pharmaceutical industry, which is highly regulated, aseptic processing is a critical component that ensures the sterility of products. Regulators have a set of comprehensive requirements that minimize the risk of contamination. Regulators set the requirements; however, the industry has an obligation to the patients who rely on and expect a drug that is safe and free of contamination....
Like any investment in digital manufacturing systems, demonstrating business payback before and after investment is critical to getting MES projects approved and verifying profitability after investment. Whether it is introducing MES, expanding it to additional sites, switching software, upgrading existing software, or developing electronic production records (EPR) for new drug products,...
Sustainability is emerging as a pivotal force influencing the pharmaceutical industry’s dynamics and steering companies towards transformative change. The focus of this analysis is to delve into the sustainability key performance indicators (KPIs) of prominent pharmaceutical players, namely Pfizer, Sanofi, Glaxo Smith Kline (GSK), Becton Dickinson, Johnson & Johnson, Abbott, Eli Lilly, and...